Anavex Life Sciences

AVXL

Market cap $342M

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present one oral late breaking communication and two poster presentations featuring blarcamesine at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, being held in San Diego, California from December 1-4, 2025. Details: Presentation #1 (LB11) Title: Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer's Disease Patients Presenter: Marwan Noel Sabbagh, MD, Professor of Neurology, and Chairman of the Anavex Scientific Advisory Board Time: December 2, 4:35 pm PT – 4:50 pm PT Presentation #2 (P076) Title: Oral Blarcamesine Comparison to Normal Cognitive Aging: Demonstrating Alignment with Prodromal Cognitive Aging Trajectories in Precision Medicine Patient Population Phase IIb/III Trial – for Early Alzheimer's Disease Patients Presenter: Audrey Gabelle, MD, PhD, Professor of Neurology, Neurologist and Member of the Anavex Scientific Advisory Board and Doctor in Neurosciences at the Memory Resources Research Center, the Rare and Early Dementia Reference Center and the European Neurodegenerative Excellence Center of Montpellier University Time: December 1, 3:00 pm PT – December 2, 5:30 pm PT Presentation #3 (P084) Title: Advancing Alzheimer's Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine Presenter: Marwan Noel Sabbagh, MD, Professor of Neurology, and Chairman of the Anavex Scientific Advisory Board Time: December 1, 3:00 pm PT – December 2, 5:30 pm PT “We are excited to present, backed up by published clinical data, oral, once daily blarcamesine with its upstream mechanism of action restoring autophagy - the key driver in restoring cellular homeostasis, which could be essential to treating Alzheimer's by activating the brain's recycling process, which is impaired in Alzheimer's disease.

Anavex Life Sciences Corp. ( AVXL ) Q4 2025 Earnings Call November 25, 2025 8:30 AM EST Company Participants Clint Tomlinson - VP of Corporate Christopher Missling - President, CEO, Secretary & Director Sandra Boenisch - Principal Financial Officer & Treasurer Conference Call Participants Michael Obodai Tom Bishop - BI Research Jesse Silveira Presentation Clint Tomlinson VP of Corporate Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2025 Fourth Quarter Conference Call. My name is Clint Tomlinson, and I'll be your host for today's call.

Company to host a webcast t oday at 8:30 a.m. Eastern Time

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th 2026, at the Westin St. Francis in San Francisco, CA. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled 4:30 PM – 5:10 PM (Pacific Time).

NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Anavex Life Sciences Corp.  ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Webcast and Conference Call To be Held Tuesday, November 25, 2025, 8:30 am ET Webcast and Conference Call To be Held Tuesday, November 25, 2025, 8:30 am ET

Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company's Alzheimer's Disease clinical trial results NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today provides a regulatory update on blarcamesine for early Alzheimer's disease. The Company was informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on the Marketing Authorisation Application (MAA) for blarcamesine following its CHMP oral explanation.

ADAS-Cog13 difference −12.78 (P < 0.0001) with oral blarcamesine treatment compared to ADNI control group at Week 144

Presentation title: “Advancing Alzheimer's Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine” Presentation title: “Advancing Alzheimer's Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine”

Anavex Life Sciences Corp. reported positive phase 2 results for ANAVEX 3-71 in schizophrenia, showing improved biomarkers and strong safety. AVXL's ANAVEX 3-71 targets all three schizophrenia domains—positive, negative, and cognitive symptoms—offering a holistic, competitive oral therapy. The company maintains a solid cash position, supporting operations for at least three years, with flexible financing options in place if needed.